Azole Resistance and Detection of the ERG11 Gene in Clinical Candida albicans Isolated from Pregnant Women with Vulvovaginitis Attending Federal Medical Centre, Yenagoa, Nigeria

Abdulrasheed B. Abdu¹, Tolulope Alade² and Catherine Omotu²

¹Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Amassoma, Bayelsa-State, Nigeria.
²Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Amassoma, Bayelsa-State, Nigeria.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/ISRR/2019/v8i230097
(1) Kailash Gupta, PhD, Program Officer, Division of AIDS, USA.
(2) Victor Baba Oti, Nasarawa State University, Nigeria.
Complete Peer review History: http://www.sdiarticle3.com/review-history/51113

ABSTRACT

Introduction: Candida albicans is one of the most important aetiological agents causing vaginal candidiasis in pregnant women. Most women will experience at least one episode during their reproductive years. Antifungal resistance is a particular problem with Candida infections. Some types of Candida are increasingly resistant to the first-line and second-line antifungal medications.

Objective: To investigate the azole susceptibility of Candida albicans (C. albicans) from pregnant vulvovaginal candidiasis patients and to detect ERG11 gene in these azole resistance isolates.

Methods: Forty-one clinical isolates of C. albicans were collected. Azole susceptibility was tested in vitro using microdilution techniques. The ERG11 genes of 27 isolates of C. albicans (All resistant to azoles) were amplified using PCR method.

*Corresponding author: Email: abdulsoul@gmail.com;
Results: Of the 67 isolates recovered, 41(61.19%) were C. albicans, of which 27 (65.85%) each, and 25(60.98%) were resistant to Fluconazole, Voriconazole, and Nystatin respectively. In total, ERG11 genes were detected among 24(88.89%) of 27 C. albicans azole resistant isolates.

Conclusions: Twenty four ERG11 genes were detected among 27 azole resistant C. albicans isolates, which indicates a possible relation with the increase in resistance to azole drugs and the recurrence of vulvovaginal candidiasis.

Keywords: Candida albicans; ERG11 gene; azole resistance; vulvovaginitis; pregnant women.

1. INTRODUCTION

Of recent, there has been a marked increase in the frequency of azole treatment failures in patients with candidiasis and are being treated for long-term antifungal therapy, this has posed a serious concern in its efficacious use in chemotherapy. Reasons had been that Candida can acquire multidrug resistance (MDR) during the course of the therapy [1,2]. Various authors have documented that Candida species possessed different mechanisms of resistance to azole antifungal agents and these mechanisms are categorised mainly as (i) changes in the cell wall or plasma membrane, which can lead to impaired drug (azole) uptake [3,4]; (ii) alterations in the affinity of the drug target Erg11p (lanosterol 14alpha-demethylase) especially to azoles or in the cellular content of Erg11p due to target site mutation or overexpression of the ERG11 gene [4,5,6,7] and (iii) the efflux of drugs mediated by membrane transport proteins belonging to the ATP-binding cassette (ABC) transporters, namely CDR1 and CDR2 or to the major facilitator superfamily (MFS) transporter, CaMDR1 [8,9]. Many such manifestations are associated with the formation of Candida biofilms, including those occurring on devices like indwelling intravascular catheters. According to Rodrigues and colleagues (2017) [3], and Sardi et al. [10], biofilm-associated Candida shows uniform resistance to a wide spectrum of antifungal drugs. Furthermore, studies conducted by Ksiezopolska and Gabaldón [1] revealed that a combination of different resistance mechanisms is responsible for drug resistance in clinical isolates of Candida species.

Flowers et al. [6] reported that in the modulation of the ERG11 gene in the ergosterol biosynthetic pathway and the alteration of the Erg11 protein targeted by azole antifungals contribute to azole resistance in C. albicans. The overexpression of ERG11 transcripts, either by gain-of-function mutations (GOF) in the transcriptional regulator, Upc2, or increased chromosome 5 copy number (on which ERG11 resides), can result in reducedazole susceptibility [11,12,13]. In addition, mutations in the Erg11 protein mediating lanosterol demethylation have been shown to alter the ability of azole antifungals to bind to and inhibit its activity and to result in enhanced resistance to this class of antifungal agents [14,15,16]. Previously, reports of mutations in ERG11 have been demonstrated on three hot spot regions analogous to amino acids 105 to 165, 266 to 287, and 405 to 488, which are particularly tolerant to amino acid substitutions [17]. Investigators have also used several approaches, which includes: heterologous expression of mutant ERG11 alleles in other microbial species (e.g. Saccharomyces cerevisiae and Pichia pastoris), enzyme inhibition with fluconazole (FLC) in cell extracts, and biochemical analysis [15,16,17,18,19] to demonstrate that ERG11 mutations can contribute to azole resistance. While a number of different amino acid substitutions have also been associated with azole resistance [18]. This study was undertaken to investigate the azole susceptibility of the clinically isolated Candida albicans (C. albicans) from vulvovaginal candidiasis (VVC) patients to three (3) antifungal routinely used in gynaecological clinics and also to detect the presence of ERG11 gene in these resistance isolates.

2. MATERIALS AND METHODS

2.1 Collection of Specimens, Isolation and Identification

Aseptically, specimens (Higher Vaginal swab “HVS”-66, and mid-stream urine catch-36) were collected from 102 pregnant women attending the Obstetrics and Gynaecology outpatient clinics in the Federal Medical Centre (a tertiary public health institution) in Yenagoa with genital infections (vulvovaginitis) in accordance to the protocols of McGowan [20] and Wang et al. [21].

Patients using any systemic or local antifungal therapy in the previous month were also included in this study.

Collected specimens were transported to the Laboratory unit of the Department of Medical
Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island for further analysis in accordance to standard procedures [20].

In the Laboratory, standard procedure was used in the inoculation of specimens. In brief, loop-full of the aseptically diluted HVS and urine specimen were aerobically cultured at 37°C for 24–48 hour on Cystine-Lactose-Electrolyte Deficient (CLED) agar, Mannitol Salt (MSA) agar, MacConkey agar, blood agar medium (Biotech Laboratories Ltd. UK) for bacteriological isolates, while, the Sabouraud Dextrose Agar (SDA, Oxoid, UK), and CHROMagar Candida (CMA; CHROMagar Company, Paris, France) were streaked for the fungi isolates. Isolates recovered from both the HVS and urine specimens were stored in 20% glycerol at -84°C.

Isolates (yeasts) on SDA were presumptively identified phenotypically as Candida by colony morphology, Gram staining, chromogenic medium (CHROMagar Candida®), and were confirmed as at the species level biochemically by the API 20C AUX yeast identification kit (bioMérieux SA, Marcy l’Etoile, France), and genetically by PCR in accordance with procedures described by Santos et al. [22] as briefly described below. C. albicans standard strain (ATCC 6258) was employed as the control.

### 2.2 DNA Extraction

The fungal DNA was extracted by boiling as described by Oliveira et al. [23]. Prior to extraction, pure isolates were subcultured in Luria-Bertani (Merck, USA) broth and incubated for 24 hours. Broth cultures were transferred to 2.0 mL Eppendorf tubes. Then, tubes were centrifuged at 10,000 rpm for 1 min and the supernatant was discarded. To dislodge the sediments, 1.5 mL sterile saline was added to the sediments and vortexed for a few seconds. This procedure was repeated twice. The tubes were then transferred to a heating block at 95°C and were heated for 20 minutes, after which they were fast freeze in a freezer (Thermocool, Nigeria) for 10 minutes.

The tubes were spun again for a minute and 300µgL of the sediment was picked and transferred to a new 1.5 mL Eppendorf tube as the DNA extract. The extracted DNA concentration was quantified by spectrophotometry. Two µgL of DNA extracted from each sample were placed directly on the spectrophotometer (NanoDrop, 2000, Thermo Scientific, USA) and measures in 260 nm. The system software provides the DNA concentration in ng/µgL (software installed on a desktop computer).

### 2.3 PCR Amplification for *Candida albicans* and of the ERG11 Gene

For genetic confirmation of the identified Candida isolates, the amplification reaction was performed following protocols reported by Vijayakumar et al. [24]. The ITS-1 and ITS-2 regions of *Candida* spp. were amplified using universal primers (Table 1). The amplification was performed in GeneAmp PCR Systems 9700 Thermal cycler (AB Applied Biosystem, USA) as previously published with modifications in the concentration of each primer (50 pmoL/reaction) and DNA template (5 IL extracted DNA/reaction), in addition to change the annealing temperature (53°C).

The amplification of the ERG11 gene was made using the following primers (Table 1). A 25µg/mL PCR mix was amplified with the following conditions: Initial denaturation at 94°C for 4 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, extension at 72°C for 1 minute and final extension at 72°C for 4 minutes. Amplified PCR products were run on 1.5% agarose gel electrophoresis and the DNA bands were visualized by UV transilluminator (BiometraTi 3) and photographed. The polymerase chain reaction (PCR) method was performed for amplification of genes with specific primers shown in Table 1.

**Table 1. Primers used in PCR**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Orientation</th>
<th>Sequence 5′ to 3′</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>rDNA</td>
<td>ITS1 FW</td>
<td>5′-TCC GTA GGT GAA CCT GCG G-3′</td>
<td>White et al. [25]</td>
</tr>
<tr>
<td></td>
<td>ITS4 RV</td>
<td>5′-TCC GCC TAT TGA TAT GC-3</td>
<td></td>
</tr>
<tr>
<td>ERG11</td>
<td>FW</td>
<td>5′-GTTGAAACTGTCAATGATG-3′</td>
<td>Martinez et al. [26]</td>
</tr>
<tr>
<td></td>
<td>RV</td>
<td>5′-TCAGAACACTGAAATCGAA-3′</td>
<td></td>
</tr>
</tbody>
</table>
2.4 Antimycotic Susceptibility Tests

The broth dilution susceptibility test was performed as recommended in the Clinical Laboratory Standards Institute (CLSI) M27-A3 reference document [27]. The antifungal agents used were Fluconazole (Sigma, UK), Nystatin (Sigma Aldrich, Steinheim, Germany) and Voriconazole (Sigma, UK).

The interpretive breakpoints for susceptibility assays were as follows. *C. albicans* strains showing minimum inhibitory concentrations (MICs) of ≤8 µg/mL, ≤16 µg/mL and ≤1 µg/mL with fluconazole, nystatin, and voriconazole, respectively were considered as susceptible (S). Strains with MIC values of ≥64 µg/mL, ≥16 µg/mL and ≥4 µg/mL with fluconazole, nystatin and voriconazole, respectively were considered as resistant (R). *C. albicans* ATCC6258 is used as control strains.

2.5 Statistical Analysis

SPSS for Windows (version 20.0; SPSS) software was used for the analysis. Frequency distribution, mean, harmonic mean, standard deviation, analysis of variance (ANOVA) were determined. Categorical variables were compared by using Pearson's chi-squared test ($\chi^2$) or Fisher's exact probability tests. P-values were calculated and $P \leq 0.05$ was considered statistically significant.

3. RESULTS

Sixty-seven (65.69%) of the genitourinary specimens collected from the 102 pregnant outpatients’ women attending the facility for suspicion of having vulvovaginitis during the period of study yielded significant microbial growth. As shown in Fig. 1, of these 67 recovered isolates, 41 (61.19%) were identified and genetically confirmed as *Candida albicans* (Fig. 2) and, the remaining ones (38.81%, n = 26) were identified to be bacteria such as *Escherichia coli* 10 (14.93%), *Staphylococcus aureus* 8 (11.94%), *Klebsiella spp.*, 6 (8.96%), and *Pseudomonas spp.* 2 (2.99%). The mean age of these women was 32 ± 9.88 years. As illustrated in Table 2, 19 (46.3%) of these isolates were recovered from HVS, while 22 (53.7%) were from urine specimens. As shown in the Table, the ratio of recovery of *C. albicans* from urine (21.52%) specimens was not significantly higher than that from the HVS (18.59%) ($P < 0.05$). Age-distribution wise, *C. albicans* were more frequent among age-group of 31-35 years with 35 (34.3%) isolates. This is followed by 26-30 years, 21-25 years, and 15-20 years with recovery rate of 31 (30.4%), 22 (21.6%) and 6 (5.9%) respectively, while the recovery rate for age 36-40, and >40 were with 4 (3.9%) each.

Table 3, shows the *in vitro* antifungal susceptibility patterns of the isolated *Candida albicans*. As shown, 27 (65.85%) of the 41 isolates were resistant to Fluconazole and Voriconazole each, while 25 (60.98%) were resistant to Nystatin. Resistance to both azoles was found in 27 (65.85%) of the strains. There was no statistically significant difference in the susceptibility of the isolates to fluconazole, Voriconazole and Nystatin ($P > 0.05$).

Twenty-four (88.89%) of the 27 isolates that were determined to be azole resistant were positive for ERGII genes (Fig. 3).

4. DISCUSSION

The study was able to isolate and identified 41 (61.19%) *Candida albicans* from the pregnant women with vulvovaginitis attending FMC, Yenagoa during the period of study. However, the presence of *E. coli*, *Klebsiella spp.*, *Pseudomonas* and *S. aureus* in some vaginal samples (n = 26) agrees with prior reports presenting bacterial vaginitis as also a cause of vaginal infections [28,29].

<table>
<thead>
<tr>
<th>Age (Years)</th>
<th>HVS</th>
<th>Urine</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-19</td>
<td>4</td>
<td>2</td>
<td>6 (5.88)</td>
</tr>
<tr>
<td>20-24</td>
<td>15</td>
<td>7</td>
<td>22 (21.57)</td>
</tr>
<tr>
<td>25-29</td>
<td>21</td>
<td>10</td>
<td>31 (30.39)</td>
</tr>
<tr>
<td>30-34</td>
<td>21</td>
<td>14</td>
<td>35 (34.31)</td>
</tr>
<tr>
<td>35-39</td>
<td>3</td>
<td>1</td>
<td>4 (3.92)</td>
</tr>
<tr>
<td>40-44</td>
<td>2</td>
<td>2</td>
<td>4 (3.92)</td>
</tr>
<tr>
<td>Total</td>
<td>66</td>
<td>36</td>
<td>102 (100.00)</td>
</tr>
</tbody>
</table>

Key: HVS, Higher vaginal Swab

| Table 2. Age distribution and recovery of microorganisms from genitourinary clinical specimens of patients from whom clinical specimens were collected |

<table>
<thead>
<tr>
<th>Antimycotic drugs</th>
<th>Fluconazole</th>
<th>Nystatin</th>
<th>Voriconazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>No (%) resistant</td>
<td>27 (65.85)</td>
<td>25 (60.98)</td>
<td>27 (65.85)</td>
</tr>
<tr>
<td>No (%) sensitive</td>
<td>14 (34.15)</td>
<td>16 (39.02)</td>
<td>14 (34.15)</td>
</tr>
</tbody>
</table>

Table 3. Susceptibility and resistance of *Candida albicans* strains isolated to antimycotic drugs
Fig. 1. Recovery of microorganisms isolated from genitourinary clinical specimens

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Percentage Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candida albicans</td>
<td>28.36</td>
</tr>
<tr>
<td>E. coli</td>
<td>10.45</td>
</tr>
<tr>
<td>Klebsiella spp.</td>
<td>8.96</td>
</tr>
<tr>
<td>Pseudomonas spp.</td>
<td>2.99</td>
</tr>
<tr>
<td>S. aureus</td>
<td>2.99</td>
</tr>
<tr>
<td>HVS</td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 2. Agarose gel electrophoresis showing ITS region of fungi (Candida species)

Lanes 1-12 represent the isolates while L represent the 100bp molecular ladder.
The outcome of this present study is in consistency with earlier reports from different parts of the world were the rates of isolation of *C. albicans* in cases of VVC has been reported to range between 47 and 89%. For illustration, studies conducted in Egypt [30] recorded higher rate of *C. albicans* in VVC (86.6%), while rates of 59%, 65.95% and 73.9% were reported from Saudi Arabia [31], Yemen [32] and Kuwait [33] respectively. Furthermore, studies from Nicaragua [34], Australia [35,36], Turkey [37], Iran [38], China [39], Nigeria [40] and India [41] collaborates this isolation range.

Among the isolates studied, there was no significant isolation rate of *C. albicans* from the HVS when compared with the urine specimen among the patients with vulvovaginitis, thus, supporting species distribution isolation rates of *C. albicans* previously reported in India [42].

The highest frequency of vaginal candidiasis was observed among age group of 31-35yrs, with the mean age of 32±9.88years. However, the frequency of vaginal candidiasis in women aged ≥ 40 years was low. This finding is similar to the previous findings reported [43,44]. Furthermore, supporting earlier observed reports that women of child bearing age groups are more susceptible to vaginal candidiasis. Similarly, Achkar and Fries [45], reported that vaginal candidiasis is an extremely common infection in 60-70% women during their reproductive age, and that every women will have candidiasis at least once in their life-time. Reasons have it that the high level of reproductive hormones and increase glycogen content of vagina favours candidiasis in pregnancy [46]. Hence this might be the common predisposing factor associated with vaginal candidiasis in the present study. Furthermore, the level of social activities, such as drug abuse and sexual promiscuity, may also be important in the distribution frequency of *Candida* species in different age groups and locations.

Due to the increased antifungal resistance of *C. albicans* species, their emergence to antimycotic agents remains a concern and this is terrifying because the indiscriminate use of azoles for the treatment of VVC over time has resulted in the selection of strains resistant to these compounds [47]. The resistance rate of our isolates to Fluconazole and Voriconazole were 27(65.85%) each. This recorded high rate is comparable to that earlier observed in various parts of the globe [28,48,49,50,51,52,53]. The level of fluconazole resistance found in this study was significantly higher, possibly because fluconazole is more frequently used in our environment. Notwithstanding, the high frequencies of strains resistant to fluconazole and Voriconazole in this study could further be explained by the high use of these fluconazole in combination with clotrimazole as prophylaxis and as the gold-standard treatment of fungal infections. Additionally, fluconazole is almost ineffective against most moulds in our environment, given that this is the most commonly used therapy against VVC. Our results are consistent with the observation that Candida species isolated in
different geographical regions differ in their sensitivity to fluconazole [54]. With this outcome, our findings negates earlier reports by Hazirolan et al. [55] that pronounces the activity of fluconazole weaker than itraconazole and that itraconazole is weaker than Voriconazole. Because, there is no significant difference in the frequency of resistance against fluconazole as observed to Voriconazole.

The *C. albicans* strains described in this study were resistant to nystatin (n = 25(60.98%). This is in sharp contrast to reports in other studies [21,28,56,57] that found nystatin to be highly efficacious. This result outcome suggests that nystatin can neither be used as empirical therapy nor as an alternative for the treatment of vaginal infections caused by strains of *C. albicans* which are resistant to azoles as earlier suggested by Achkar & Fries [45]. There is need to draw the attention of clinicians in our environment to this situation so that they can seek improve treatment via different approaches, which may include the combination (synergistic) of antifungals as evidence has shown that combinatory therapy contributes to reducing toxicity and could be an alternative for treatment of candidiasis due to *C. albicans* [58, 59]. However, the possibility of some system bias cannot be excluded due to the potential reasons of the different specimen, test method, and regional disparity [60,61].

In this study, the association of azole resistance phenotypes (fluconazole/Voriconazole) was identified in 27(65.85%) of the strains (Table 3), whereas *ERG11* was found in 24(88.89%) (Fig 3). The detection of *ERG11* genes conforms with several studies that have implicated this gene to azole resistances [11,18,28,48,62,63,64,65,66].

However, the gap difference of 3(11.11%) in the detection of this gene in the present study can be explained by the idea that azole resistance is not only conferred by *ERG11* gene alone, but also caused by *CDR1*, an ATP-binding cassette (ABC) transporter [63,64] or by MFS-transporter, *CaMDR1* [8,9]. A better understanding of this mechanism of resistance to these agents as well as detection of *ERG11* genes are essential for the patient management, as the *ERG11* gene has been linked to clinically-relevant increases to azoles and which is also correlated with the increase in recurrence of VVC [21].

5. CONCLUSION

This study found that *C. albicans* was associated with VVC among the pregnant women and that the strains that infects Yenagoa patients suffering from VVC are highly resistant to azoles, nystatin and that those resistant to the azoles are harbouring *ERG11* genes. It is therefore vital that regimens should be adjusted according to local surveillance and *in vitro* susceptibility results, as high-level azole resistance is a problem of critical importance in our setting.

CONSENT AND ETHICAL APPROVAL

The study was approved by the Research and Ethical Committee of The Federal Medical Centre, Yenagoa (Ref. No. FMC/REC/19/013). Informed consent was also obtained from all individual participants included in this study.

ACKNOWLEDGEMENT

We are grateful to members of staff of the Departments of Obstetrics & Gynecology and Medical laboratory Science (Microbiology unit) of the Federal Medical Centre, Yenagoa for allowing us access to their patients and assisting in specimen collections. We are also grateful to the participating patients for partaking in this study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


Available:https://doi.org/10.1155/2014/541340


© 2019 Abdu et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.